Summary
MannKind Corporation (MannKind) is a bio-pharmaceutical company. It focuses on the discovery, development and commercialization of therapeutic products to treat diseases such as diabetes and cancer. The company’s product pipeline include its lead product, MannKind Corporation (MannKind) is a bio-pharmaceutical company. It focuses on the discovery, development and commercialization of therapeutic products to treat diseases such as diabetes and cancer. The company’s product portfolio comprises one marketed product Afrezza, a rapid-acting inhaled insulin aimed to enhance glycemic control and is indicated for the treatment of diabetes. Afrezza is the only approved inhaled insulin for the treatment of diabetes in the US. The company develops its products based on its proprietary formulation technology Technosphere. MannKind’s clinical research and development operations are conducted in Paramus, New Jersey and its manufacturing operations are carried out in Danbury, Connecticut. The company has a global licensing agreement with Sanofi for the commercialization of Afreeza. MannKind is headquartered in California, the US. MannKind aims to support the recent launch of Afreeza in February 2015 and support the manufacture and adequate supply of the product in the US according to the requirement.
MannKind Corporation (MNKD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
MannKind Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
MannKind Corporation, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
MannKind Corporation, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
MannKind Corporation, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
MannKind Corporation, Medical Devices Deals, 2010 to YTD 2016 9
MannKind Corporation, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
MannKind Corporation, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Dana-Farber Cancer Institute Enters into Agreement with MannKind 12
Herborium Expands Distribution Agreement With MannKind 13
MannKind Plans To Enters Into An Agreement For Afrezza 14
Licensing Agreements 15
Receptor Life Sciences Enters into Licensing Agreement with MannKind 15
MannKind Terminates Licensing Agreement with Sanofi for Afrezza 16
Colby Enters Into Licensing Agreement With MannKind For Cancer Immunotherapy Products 18
MannKind Enters Into Licensing Agreement With Tolero Pharma For Bruton’s Tyrosine Kinase Inhibitors 20
Equity Offering 22
MannKind Prices Private Placement of Shares for USD36.2 Million 22
MannKind Announces Public Offering Of Common Stock For US$50 Million 24
MannKind Completes Public Offering Of Common Stock And Warrants For US$92 Million 25
MannKind Completes Public Offering Of Units For US$86 Million 27
MannKind Completes Private Placement Of Common Stock 29
Debt Offering 31
MannKind Completes First Tranche Of Private Placement Of Notes For US$40 Million 31
MannKind Plans Public Offering Of Senior Secured Discount Notes Due 2017 For US$370 Million 33
MannKind Completed Private Placement Of Senior Convertible Notes Due 2015 For US$100 Million 34
Acquisition 35
MannKind May Sell Itself 35
MannKind Corporation - Key Competitors 36
Key Employees 37
Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39
List of Tables
MannKind Corporation, Pharmaceuticals & Healthcare, Key Facts, 2014 1
MannKind Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
MannKind Corporation, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
MannKind Corporation, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
MannKind Corporation, Deals By Therapy Area, 2010 to YTD 2016 8
MannKind Corporation, Medical Devices Deals, 2010 to YTD 2016 9
MannKind Corporation, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 10
Dana-Farber Cancer Institute Enters into Agreement with MannKind 12
Herborium Expands Distribution Agreement With MannKind 13
MannKind Plans To Enters Into An Agreement For Afrezza 14
Receptor Life Sciences Enters into Licensing Agreement with MannKind 15
MannKind Terminates Licensing Agreement with Sanofi for Afrezza 16
Colby Enters Into Licensing Agreement With MannKind For Cancer Immunotherapy Products 18
MannKind Enters Into Licensing Agreement With Tolero Pharma For Bruton’s Tyrosine Kinase Inhibitors 20
MannKind Prices Private Placement of Shares for USD36.2 Million 22
MannKind Announces Public Offering Of Common Stock For US$50 Million 24
MannKind Completes Public Offering Of Common Stock And Warrants For US$92 Million 25
MannKind Completes Public Offering Of Units For US$86 Million 27
MannKind Completes Private Placement Of Common Stock 29
MannKind Completes First Tranche Of Private Placement Of Notes For US$40 Million 31
MannKind Plans Public Offering Of Senior Secured Discount Notes Due 2017 For US$370 Million 33
MannKind Completed Private Placement Of Senior Convertible Notes Due 2015 For US$100 Million 34
MannKind May Sell Itself 35
MannKind Corporation, Key Competitors 36
MannKind Corporation, Key Employees 37
MannKind Corporation, Other Locations 38
List of Figures
MannKind Corporation, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
MannKind Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
MannKind Corporation, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
MannKind Corporation, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
MannKind Corporation, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
MannKind Corporation, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 6
MannKind Corporation, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
MannKind Corporation, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
MannKind Corporation, Medical Devices Deals, 2010 to YTD 2016 9